|
| |
SOLEXA TO PRESENT AT RODMAN
AND RENSHAW TECHVEST 7TH ANNUAL HEALTHCARE CONFERENCE
HAYWARD, Calif. and Cambridge, UK (November 1, 2005) – Solexa, Inc. (Nasdaq:
SLXA) today announced that John West, Chief Executive Officer of Solexa, will
make a presentation to the investment community at the Rodman & Renshaw Techvest
7th Annual Healthcare Conference on Tuesday, November 8, 2005 at 4:35 p.m.
Eastern Time (1:35 p.m. Pacific Time), at the Palace Hotel in New York City.
Interested investors may gain access to a live audio webcast and slide
presentation via the Internet by visiting the “News – Conferences and
Exhibitions” section of the company’s Web site at
www.solexa.com . The presentation will be
archived on the Web site and available for 14 days.
About Solexa
Solexa, Inc. is developing and preparing to commercialize a new genetic analysis
instrument system which will be used to perform a range of analyses including
whole genome resequencing, gene expression analysis and micro-RNA analysis.
Solexa expects its first-generation technology to generate over a billion bases
of DNA sequence per run and to enable whole genome resequencing below $100,000
per sample, making it the first platform to reach this important milestone.
Solexa's longer-term goal is to reduce the cost of human resequencing to a few
thousand dollars for use in a wide range of applications from basic research
through clinical diagnostics. The Company expects to introduce its first
instrument system by the end of 2005. For further information, please visit
www.solexa.com .
This press release contains "forward-looking" statements, including statements
related to the current views of Solexa management as to future products, product
development including the commercial introduction of the Company’s novel genetic
analysis technology, the expansion and success of Solexa's commercial
application of its genomics technologies, the availability of adequate funding
for Solexa and the future financial performance of Solexa. Any statements
contained in this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Words such as "believes,"
"anticipates," "plans," "predicts," "expects," "envisions," "hopes,"
"estimates," "intends," "will," "continue," "may," "potential," "should,"
"confident," "could" and similar expressions are intended to identify
forward-looking statements. There can be no assurance that such expectations of
any of the forward-looking statements will prove to be correct, and actual
results could differ materially from those projected or assumed in the
forward-looking statements. There are a number of important factors that could
cause the results of Solexa to differ materially from those indicated by these
forward-looking statements including, among others, risks detailed from time to
time in the Company's SEC reports, including its Annual Report on Form 10-K for
the year ended December 31, 2004 and its Form 10-Q for the quarter ended June
30, 2005. Solexa does not undertake any obligation to update forward-looking
statements.
###
For more information, please contact:
Solexa, Inc.
Omead Ostadan, Vice President of Marketing
(510) 670-9300
oostadan@solexa.com
European Media Contact:
Northbank Communications
Sue Charles, CEO
+44 (0)20 7886 8152
s.charles@northbankcommunications.com
U.S. Media Contact:
Mark Stuart (mstuart@lhai.com )
(310) 691-7100
Lippert/Heilshorn & Associates
Investor Contacts:
Jody Cain
(jcain@lhai.com )
Mariann Ohanesian (mohanesian@lhai.com
)
| |
|
